PRPF31 and mycosis fungoides: Comparing this compartment in MF patients with progression vs. non-progression, we found upregulation of RUNX2 (p=.002, FDR=.91), ATP5ME (p=.000, FDR=.99), CD37 (p=.003, FDR=.99), TIMM13 (p=.004, FDR=.99), LPIN3 (p=.006, FDR=.99), SHMT2 (p=.014, FDR=.99), SP1 (p=.004, FDR=.99), UPF2 (p=.008, FDR=.99), AKAP1 (p=.009, FDR=.99), SLC16A3 (p=.009, FDR=.99), MCM7 (p=.013, FDR=.99), PSTPIP1 (p=.014, FDR=.99), PRPF31 (p=.016, FDR=.99) and ZNF419 (p=.007, FDR=.99) in malignant CD4+ T-cells in Pautrier’s microabscesses in MF patients with progression compared with the non-progression group (Figure 2B).